Partnership launches AI solution to enhance predictive heart valve visualization and personalize valve treatment planning decisions enabling the future of TAVR for structural heart patients

DUBLIN, OH / ACCESS Newswire / October 21, 2025 / Medtronic plc, a global leader in healthcare technology, and DASI Simulations, a leader in AI-driven predictive modeling and digital-twin technology, today announced a strategic partnership to enhance access to DASI technology to optimize outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the United States.

This program marks a significant step forward in both Medtronic's and DASI's mission to deliver innovative, patient-specific care. By integrating DASI Simulations' advanced AI-based predictive modeling and digital twin technology into the TAVR workflow, clinicians will gain access to independent and device-agnostic actionable insights that support more precise, individualized treatment decisions for patients living with aortic stenosis.

"Effective pre-case planning is essential to achieving optimal outcomes in TAVR," said Matthew Summers, MD, interventional cardiologist at Sentara Heart Hospital. "Integrating DASI's predictive modeling into our workflow has allowed us to better visualize anatomy, anticipate risks, and tailor valve decisions to each patient. It's helped us focus on individual factors like annular rupture, coronary occlusion, and paravalvular leak, while also planning for future reinterventions."

"Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide," said Teri Sirset, MS, founder, president, and chief executive officer of DASI Simulations. "Together, we're demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care."

DASI's FDA-cleared platform leverages real patient computerized tomography (CT) anatomies and retrospective outcomes to simulate multiple transcatheter heart valve (THV) deployment scenarios. Using these data-driven reports - rooted in independent device-agnostic, patient-specific predictive modeling - will help mitigate human error, predict complications, and optimize long-term management for structural heart patients.

"The future of TAVR lies in delivering patient-specific, data-driven care that spans the full patient journey, from therapy awareness and innovation to procedural excellence and options for future intervention," said Jorie Soskin, vice president and general manager of the Structural Heart business within the Cardiovascular portfolio at Medtronic.

Participating sites will receive full support from both Medtronic Structural Heart and DASI Simulations teams. The program is designed to demonstrate the clinical and operational value of integrating simulation-based planning to enable device agnostic, patient-specific TAVR care.

"We are entering a new era in structural heart care, guided by predictive AI models that help the physician determine the best treatment personalized for each patient, rather than relying on statistical norms. This shift to precision medicine will transform how we treat structural heart diseases," said Lakshmi Dasi, PhD, founder and chief technology officer at DASI Simulations. "DASI is the pioneer for AI-based predictive modeling for TAVR, and our platform is designed to support unbiased and device agnostic decision-making with the patient at the center that will ultimately support more confident, personalized interventions."

SOURCE: DASI Simulations